Modulation of nitric oxide activity through blockade of CD47 signaling has been shown to reduce ischemia-reperfusion injury (IRI) in various models of tissue ischemia. Here, we evaluate the potential effect of an antibody-mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant model. The donor organ was subjected to 1 hour of warm ischemia time after circulatory cessation, then flushed with a CD47 monoclonal antibody (CD47mAb) in the treatment group, or an isotype-matched immunoglobulin in the control group. We found that CD47mAb treatment improved survival rates in both models. Serum markers of renal injury were significantly decreased in the CD47mAb-treated group compared with the control group. Histologically the CD47mAb-treated group had significantly reduced scores of acute tubular injury and acute tubular necrosis.
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Modulation of nitric oxide activity through blockade of CD47 signaling has been shown to reduce ischemia-reperfusion injury (IRI) in various models of tissue ischemia. Here, we evaluate the potential effect of an antibody-mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant model. The donor organ was subjected to 1 hour of warm ischemia time after circulatory cessation, then flushed with a CD47 monoclonal antibody (CD47mAb) in the treatment group, or an isotype-matched immunoglobulin in the control group. We found that CD47mAb treatment improved survival rates in both models. Serum markers of renal injury were significantly decreased in the CD47mAb-treated group compared with the control group. Histologically the CD47mAb-treated group had significantly reduced scores of acute tubular injury and acute tubular necrosis.
The expression of biomarkers related to mitochondrial stress and apoptosis also were significantly lower in the CD47mAb-treated groups. Overall, the protective effects of CD47 blockade were greater in the syngeneic model. Our data show that CD47mAb blockade decreased the IRI of DCD kidneys in rat transplant models. This therapy has the potential to improve DCD kidney transplant outcomes in the human setting.
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| INTRODUCTION
Kidney transplantation is still the optimal choice for patients with end-stage renal disease. However, the shortage of donor kidneys is a severe problem worldwide, 1 and waitlist times continue to grow in the United States. Using kidneys from donation after cardiac death (DCD) is an important way to expand the donor pool. Based on Organ
Procurement and Transplantation Network data as of December 31, 2015 , the number of DCD donors increased each year in the last 2 decades in the United States, from 64 in 1995 to 1494 in 2015.
However, one of the major potential complications with DCD kidneys is the higher incidence of delayed graft function (DGF) compared with kidneys from donation after brain death (DBD).
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Ischemia-reperfusion injury (IRI) is one of the most important causes of DGF. 5 Compared with DBD donors, longer warm ischemia times after cardiac arrest in DCD donors reduces oxygen and nutrient supply to the tissues, leading to increased IRI and reduced kidney quality. A recent study reported that greater warm ischemia times are associated with higher rates of graft failure and mortality after kidney transplantation. 6, 7 IRI can also lead to progressive graft dysfunction with chronic fibroinflammatory changes that impact longterm graft survival. 8, 9 It is therefore essential to develop strategies to prevent or ameliorate IRI and improve the quality of DCD allografts. 
| MATERIALS AND METHODS

| Animals
Male Lewis and Brown Norway rats (275-300 g; Charles River
Laboratories, Wilmington, MA) were acclimated for at least 72 hours prior to the experiments. They were given free access to standard rodent food and water ad libitum before and after transplantation except for fasting 12 hours before surgery. Animal experimental protocols were approved by the Animal Studies Committee at Washington University School of Medicine in St. Louis.
| Rat DCD kidney transplant IRI model and anti-CD47 monoclonal antibody treatment
The syngeneic (Lewis) or an allogeneic (Brown Norway) donor animal was anesthetized with 2% isoflurane. After intravenous heparinization (200 U), cardiac arrest was induced by opening the chest. The cessation of the heartbeat was observed within 2-3 minutes, and the donor animals were kept for 1 hour on a 37°C pad. The left kidney was mobilized, the aorta was clamped proximal and distal to the renal arteries, and the kidneys were perfused using a 25-gauge needle with 5 mL of UW solution containing 50 μg of control IgG isotype or a humanized anti-CD47 monoclonal antibody (CD47mAb; Tioma Therapeutics, Inc., St. Louis, MO) into the renal artery. The infrarenal inferior vena cava was transected distal to the renal veins. The left kidney was then placed in cold storage for 6 hours.
A Lewis recipient was then anesthetized and a left nephrectomy was performed. The transplant procedure was performed as previously described. 13 The allogeneic recipients received 1 dose of tacrolimus (0.2 mg/kg, iv) after reperfusion of the kidney. The ureter was anastomosed to the bladder, and a right nephrectomy was performed.
The first set of experiments was performed to assess posttransplant survival (syngeneic model n = 20, 10 for each group and allogeneic model n = 12, 6 for each group). Transplanted rats that survived to day 7 were euthanized. A second set of experiments (syngeneic model n = 10, 5 for each group and allogeneic model n = 10, 5 for each group) was performed using the same experimental design to assess renal function, histological injury, and apoptosis and the animals were euthanized 48 hours after transplantation.
| Renal function assays
Blood samples of the recipients were collected at 48 hours after kidney transplantation. Serum creatinine, blood urea nitrogen (BUN), potassium, and phosphorus were measured using a Beckman AU480
Chemistry Analyzer (Beckman Coulter, Brea, CA).
| Histology and immunohistochemistry
The recipient animals were euthanized on postoperative day 2, at which time the graft was recovered, and portions were preserved in 
| Western blot assay
Cytokeratin 18, PARP, VDAC-1, caspase-3, caspase-8, and caspase-9
protein levels in the kidneys were measured using Western blot assay.
Ice-cold lysis buffer was used to homogenize renal tissues. 
| Statistical analysis
Statistical analyses were performed using Prism (GraphPad Software, San Diego, CA). Survival analysis was performed using Kaplan-Meier analysis and the log-rank test. Data are expressed as mean ± standard error of the mean. Comparisons between groups were performed using Student t test. Differences with P values <.05 were considered to be statistically significant.
| RESULTS
| Treatment with CD47mAb improved rat DCD kidney transplant survival
To assess the ability of antibody-mediated CD47 blockade to improve DCD graft function, we performed experiments in both syngeneic and allogeneic rat transplant models of kidney transplant in bilaterally nephrectomized recipients. Our first set of experiments was designed to assess the survival benefit of CD47 blockade after transplantation.
We found that treatment with CD47mAb significantly improved the survival rate in both the syngeneic and allogeneic DCD kidney models ( Figure 1 , P < .001 and P < .002, respectively). However, no recipients survived more than 7 days in the allogeneic model.
| Treatment with CD47mAb improved graft renal function
Renal function was evaluated 48 hours after kidney transplantation.
We measured serum creatinine, BUN, potassium, and phosphorus.
Creatinine (1.0 ± 0.1 mg/dL; vs 5.8 ± 0.1 mg/dL; P < .001, Figure 2A ), BUN (50.1 ± 7.9 mg/dL; vs 207.0 ± 2.0 mg/dL; P < .001, Figure 2B ), potassium (4.5 ± 0.2 mmol/L; vs 7.4 ± 0.2 mmol/L; P < .001, Figure 2C ), and phosphorus (6.1 ± 0.6 mg/dL; vs 19.4 ± 0.3 mg/dL; P < .001, Figure 2D ) levels were significantly lower in the CD47mAb-treated group compared with the IgG-treated control group after kidney transplantation in the syngeneic model. In the allogeneic model, creatinine (4.0 ± 0.7 mg/dL; vs 6.9 ± 0.3 mg/dL; P = .005, Figure 2A ), BUN (140.4 ± 11.1 mg/dL; vs 191.5 ± 4.8 mg/dL; P = .003, Figure 2B ), potassium (5.0 ± 0.4 mmol/L; vs 6.6 ± 0.3 mmol/L; P = .016, Figure 2C ), and phosphorus (12.0 ± 2.0 mg/dL; vs18.3 ± 1.0 mg/ dL; P = .024, Figure 2D ) levels were also significantly lower in CD47mAb-treated group compared with the IgG-treated control group. Comparing the results of the 2 different models, the reductions in creatinine and BUN levels in the CD47mAb-treated group were greater in the syngeneic than in the allogeneic model ( Figure 2A and B, P < .001, respectively).
| Treatment with CD47mAb reduced ATI and ATN
Because we were not able to collect serum and graft tissue from the survival experiments, we performed another set of experiments under identical conditions and concluded the experiments at 48 hours, at which time serum and the transplanted kidneys were collected for further study. We first evaluated the grafts for histological evidence of IRI. ATI and ATN were characterized as tubular dilatation, epithelial flattening, cell sloughing, or coagulative necrosis. Histological sections were evaluated and scored in a blinded manner by a renal pathologist.
Histological evaluation showed that the CD47mAb-treated group had significantly decreased scores of ATI (7 ± 1% vs 48 ± 6%, P < .001) and ATN (17 ± 2% vs 57 ± 8%, P = .001) in the syngeneic model. In the allogeneic model, ATI (11 ± 3% vs 50 ± 8%, P = .002) and ATN (19 ± 4% vs 62 ± 8%, P = .002) were also significantly reduced in the CD47mAb-treated kidneys ( Figure 3 ).
F I G U R E 1 Treatment of the kidney graft with CD47mAb improves posttransplant survival rate in 2 rat DCD renal transplant models. A, Syngeneic kidney transplant model, Kaplan-Meier survival analysis of the study group showed an increase in CD47mAb group survival. B, Allogeneic renal transplant model also showed an increase in CD47mAb group survival. CD47mAb, anti-CD47 monoclonal antibody; DCD, donation after cardiac death
| CD47mAb treatment decreased the inflammatory response
We next investigated the extent of CD3 + T cell infiltration in the graft tissue to assess the inflammatory response after kidney transplantation. As shown in Figure 4A 
potassium, and (D) phosphorus were measured using an autoanalyzer. Two days after transplantation, serum creatinine, BUN, potassium, and phosphorus were significantly lower in rats that received the CD47mAb-treated kidneys than the IgG-treated control kidneys. BUN, blood urea nitrogen; CD47mAb, anti-CD47 monoclonal antibody F I G U R E 3 CD47mAb-treated donor kidneys exhibit histological evidence of IRI protection. A, In the syngeneic model and the allogeneic model, CD47mAb-treated donor kidneys showed less histological injury when examined 48 h after transplantation (magnification ×200) than kidneys receiving control IgG antibody. B, Histological sections were scored in a blinded manner for ATI and ATN. The CD47mAb-treated groups had significantly decreased scores of ATI and ATN in both models. ATI, acute tubular injury; ATN, acute tubular necrosis; CD47mAb, anti-CD47 monoclonal antibody; IRI, ischemia-reperfusion injury
| CD47mAb treatment reduces oxidative stress
Under DCD conditions, the donor organs are subjected to prolonged warm ischemia times during which renal cellular mitochondria remain hypoxic. To evaluate mitochondrial stress, we measured the expression of keratin K18, a sensitive marker of renal tubular cell stress, 14 in the graft tissue. Immunofluorescent (IF) histological staining showed that K18 was much lower in the CD47mAb-treated groups in both syngeneic and allogeneic models ( Figure 5A ). Western blot and densitometry analysis found that K18 levels were markedly lower F I G U R E 4 CD47mAb treatment decreased the inflammatory response of the DCD renal grafts. A, CD3 + T lymphocytes were visualized by immunofluorescence staining in renal tissue at 48 h after transplantation (magnification ×400). B, The number of infiltrating CD3 + cells
were quantified and found to be significantly decreased in the CD47mAb-treated renal grafts vs the control group in both the syngeneic and allogeneic models. CD47mAb, anti-CD47 monoclonal antibody; DAPI, 4′,6-diamidino-2-phenylindole; DCD, donation after cardiac death F I G U R E 5 CD47mAb treatment reduced renal tubular cell stress after kidney transplantation. A, IF histology staining of K18 (magnification ×400), colocalized with AQP2 as a marker of the collecting ducts, indicated that CD47mAb treatment reduced expression of K18 in both syngeneic and allogeneic models. B, Western blot and densitometry analysis found that K18 levels were markedly lower in the CD47mAb-treated group in the syngeneic model, while in the allogeneic model, there was no significant difference. CD47mAb, anti-CD47 monoclonal antibody; DAPI, 4′,6-diamidino-2-phenylindole; IF, immunofluorescent; K18, keratin 18 in the CD47mAb-treated group in the syngeneic model (P < .002).
Similarly, in the allogeneic model, the levels of K18 were numerically lower in the CD47mAb-treated group but did not reach significance ( Figure 5B , P = .110).
We next examined the expression of PARP, which is involved in the cellular response to DNA and mitochondrial damage. IF staining indicated that PARP was much lower in the graft tissues of the CD47mAb-treated group, both in the syngeneic and allogeneic models ( Figures 6A   and 7A ). Western blot and densitometry analysis showed that in the CD47mAb-treated groups, PARP expression was significantly reduced when compared with IgG control groups ( Figures 6B and 7B , P < .001
and P = .044, respectively). VDAC-1 is also involved in the regulation of cell metabolism and mitochondrial stress. IF staining of VDAC-1 was also lower in the CD47mAb-treated group in both syngeneic and allogeneic models ( Figures 6A and 7A) . Western blot and densitometry analysis revealed that in the syngeneic model, VDAC-1 expression was significantly reduced in the CD47mAb-treated group when compared with the IgG control group ( Figure 6B , P = .001). However, there was no significant difference in the allogeneic model ( Figure 7B ).
| CD47mAb treatment reduces kidney cell apoptosis
IRI has been shown to induce apoptosis in kidney cells. 15 We therefore examined the effect of CD47 blockade on the apoptotic response to IRI using both Western blot and IF analysis of caspase-9, caspase-8, and caspase-3 expression. IF staining indicated that the expression of caspase-3 was much lower in the CD47mAb treatment group when compared with the control group in both syngeneic and allogeneic models ( Figures 8A and 9A) . Western blotting and densitometry F I G U R E 6 Syngeneic rat DCD renal transplant model. CD47mAb treatment reduced oxidative stress. A, IF staining of PARP and VDAC-1 (magnification ×200) showed that they were expressed lower in the CD47mAb-treated group. B, Western blot and densitometry analysis showed that expression of activated PARP and VDAC-1 were markedly lower in the CD47mAb-treated group compared to the IgG control group. CD47mAb, anti-CD47 monoclonal antibody; DAPI, 4′,6-diamidino-2-phenylindole; DCD, donation after cardiac death; IF, immunofluorescent; PARP, poly (ADP-ribose) polymerase; VDAC-1, voltage-dependent anion-selective channel protein 1 analysis confirmed the findings of IF staining, and it also showed that caspase-9 and caspase-8 expression were significantly reduced in CD47mAb-treated recipients ( Figures 8B and 9B ).
| DISCUSSION
In this study, we evaluated the potential effect of CD47mAb treatment in a syngeneic and an allogeneic DCD rat kidney transplant model. CD47mAb treatment administered by flush to the donor organ improved overall survival of recipients and reduced kidney damage (ATN and ATI). In both models, the graft function improved significantly in the CD47mAb-treated group when compared with the control group. However, possibly due to the confounding effects of the immune response in the allogeneic model, serum biomarkers such as creatinine and BUN were not reduced to the same magnitude as in the syngeneic model. We also demonstrated that CD47mAb could reduce mitochondrial stress as well as apoptosis.
In our previous studies, we demonstrated the effectiveness of CD47 blockade in reducing IRI in SCD rat kidney and liver transplant models. 13, 16 TSP-1-induced CD47 receptor activation inhibits the NO signaling pathway, which can lead to vasoconstriction, apoptosis, thrombosis, and inflammation. Therefore, modulation of NO signaling through blockade of CD47 signaling has been shown to be an F I G U R E 7 Allogeneic rat DCD renal transplant model. CD47mAb treatment reduced mitochondrial oxidative stress. A, IF staining of PARP and VDAC-1 (magnification ×200) showed that they were expressed lower in the CD47mAb-treated group. B, Western blot and densitometry analysis showed that expression of activated PARP was significantly lower in the CD47mAb-treated group compared to the IgG control group; however, there was no significant difference in VDAC-1 expression. CD47mAb, anti-CD47 monoclonal antibody; DAPI, 4′,6-diamidino-2-phenylindole; DCD, donation after cardiac death; IF, immunofluorescent; PARP, poly (ADP-ribose) polymerase; VDAC-1, voltage-dependent anion-selective channel protein 1 effective mitigator of IRI in various models of tissue ischemia. Other studies also found that therapies targeting the TSP-1 receptor CD47
offer the potential for increasing tissue survival and decreasing tissue damage in IRI. [17] [18] [19] A recent study showed that treatment with a CD47-blocking antibody increased self-renewal transcription factor expression and alleviated IRI in a syngeneic kidney transplant model. 20 These studies suggest that CD47 blockade may have therapeutic potential to reduce IRI in organ transplantation. Whereas these studies used either transient ischemia or SCD syngeneic transplant models, we extended our evaluation using allogeneic and DCD transplant models.
The incidence of DGF is much higher in DCD kidneys than DBD kidneys, 2, 5, 21 which is attributed to exposure of DCD kidneys to hypoperfusion, hypoxia, and inflammation during prolonged warm ischemia and reperfusion. 22, 23 In our study, we used 1 hour of warm ischemia time after circulatory arrest to induce a measure of damage from which we could investigate the protective effects of CD47mAb
treatment. Although we demonstrate that both syngeneic and allogeneic DCD kidney transplant recipients benefited from CD47mAb therapy, no recipients survived beyond 7 days in the allogeneic model, and 30% CD47mAb-treated recipients were alive at 7 days, indicating that the DCD model with 1 hour of warm ischemia after circulatory arrest resulted in severe tissue damage. This is in contrast to the human transplant setting with DCD donors, where "donor warm ischemia time" usually denotes the time after withdrawal of treatment. 22, 24 Although perfusion is reduced during this period, oxygen delivery continues to occur, and the actual ischemic time after complete cessation of circulation is typically less than 10 minutes. Despite the severity of our DCD model, we were able to demonstrate meaningful improvement of transplant outcomes with CD47mAb treatment of the graft.
It has been reported that inflammatory cells including T helper cells, neutrophils, and macrophages play an important role in renal IRI. 25, 26 Several studies showed that blocking CD47 could inhibit IL-12-driven Th1 cell development and IL-2 response of activated naïve T cells. 27, 28 Our previous study also found that CD47mAb treatment reduced the proinflammatory response in the transplanted rat liver.
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In this study, outcome of immunofluorescence staining indicated that CD47mAb treatment remarkably lowered the CD3 + T cell infiltration of the renal grafts in both syngeneic and allogeneic models, although it was less striking in the allogeneic model. These results provide evidence that the improved transplant outcomes following CD47mAb treatment could be due in part to the decreased inflammatory response in the DCD kidney grafts. Although in the allogeneic model, the BUN and creatinine were significantly lower in the CD47mAb-treated group than the control group, they were higher than in the syngeneic model. One limitation of our model was the use of just 1 dose of immunosuppressive drugs that was administered just after reperfusion in the allogeneic model as more aggressive immunosuppression was not well tolerated. This lower dose of immunosuppression likely resulted in some increased graft damage due to the remaining, but reduced immune response that was not present in the syngeneic model.
In the current study, we evaluated oxidative stress and apoptosis in DCD kidney transplantation by several biomarkers of IRI.
F I G U R E 8 Syngeneic rat DCD renal transplant model. CD47mAb treatment reduced cell apoptosis. A, IF staining of caspase-3 (magnification ×200) showed it was expressed lower in the CD47mAb-treated group. B, Western blot and densitometry analysis showed that expression of activated caspase-3, caspase-8, and caspase-9 were significantly lower in CD47mAb-treated group compared to the IgG control group. CD47mAb, anti-CD47 monoclonal antibody; DAPI, 4′,6-diamidino-2-phenylindole; DCD, donation after cardiac death; IF, immunofluorescent
Keratins are upregulated in stress situations and recognized as novel markers of renal epithelial cell injury.
14 In this study, we found that K18 was much lower in the CD47-treated groups compared to controls. However, the Western blotting analysis showed that there was no significant difference in the allogeneic model. This may be due to the more severe damage in the allogeneic recipients.
PARP activation induces ATP depletion by promoting mitochondrial damage and then induces reactive oxygen species production, elevates intracellular Ca 2+ ,, and destabilizes the mitochondrial membrane system leading to mitochondrial permeability transition and cell death. [30] [31] [32] A recent study found that PARP increases the expression of inflammatory mediators such as cytokines, inducible NO synthase, and adhesion molecules. 33 In our study, we found that CD47mAb-treated recipients had significantly lower PARP expression compared with the IgG-treated control group. VDAC-1 is a protein involved in the regulation of cell metabolism and mitochondrial apoptosis. Some studies have demonstrated that downregulated VDAC-1 leads to prevention of mitochondrial permeability transition pore opening and cell apoptosis. [34] [35] [36] [37] We also found that CD47mAb-treated recipients had significantly lower VDAC-1 expression compared with the IgG-treated control group in the syngeneic model.
Caspases are a family of protease enzymes playing essential roles in programmed cell death and inflammation. Caspase-3 is a classic biomarker of apoptosis. Caspase-8 and caspase-9 are initiators, while caspase-3 is an executioner. In the intrinsic apoptotic pathway, during cellular stress, active capase-9 will cleave and activate caspase-3, then lead to degradation of cellular components for apoptosis. [38] [39] [40] In the extrinsic apoptotic pathway, activated caspase-8 can lead to either downstream activation of the intrinsic pathway by inducing mitochondrial stress, or direct activation of caspase-3 activation and apoptosis. [41] [42] [43] Our study showed that caspase-3, caspase-8, and caspase-9
were all significantly lower in the CD47mAb-treated group in both allogeneic and syngeneic models. All these biomarkers demonstrated that CD47mAb therapy could decrease oxidative stress, mitochondrial damage, and apoptosis, reducing IRI and providing renal protection in DCD kidney transplantation.
In conclusion, our data showed that CD47mAb treatment could significantly reduce IRI after kidney transplantation in both syngeneic and allogeneic DCD models. This therapy has the potential to increase use of DCD kidneys and improve DCD kidney transplant outcomes in the human setting. F I G U R E 9 Allogeneic rat DCD renal transplant model. CD47mAb treatment reduced cell apoptosis. A, IF staining of caspase-3 (magnification ×200) was reduced in the CD47mAb-treated group compared to control. B, Western blot and densitometry analysis showed that expression of activated caspase-3, caspase-8, and caspase-9 were significantly reduced in the CD47mAb-treated group compared to the IgG control group. CD47mAb, anti-CD47 monoclonal antibody; DAPI, 4′,6-diamidino-2-phenylindole; DCD, donation after cardiac death; IF, immunofluorescent
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